Name: AcLys-PABC-VC-Aur0101
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

[4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]carbamate

Canonical SMILES

CC(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(NC(C)(C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N2[C@H]([C@@H]([C@H](C(N[C@@H](CC3=CC=CC=C3)C4=NC=CS4)=O)C)OC)CCC2)=O)=O)=O)=O)C=C1)=O)=O)=O)=O

InChI

InChI=1S/C66H103N13O13S/c1-14-41(6)55(51(90-12)37-52(81)79-34-21-26-50(79)56(91-13)42(7)57(82)74-49(61-69-33-35-93-61)36-44-22-16-15-17-23-44)78(11)62(86)54(40(4)5)76-63(87)66(9,10)77-65(89)92-38-45-27-29-46(30-28-45)72-58(83)48(25-20-32-70-64(68)88)73-60(85)53(39(2)3)75-59(84)47(71-43(8)80)24-18-19-31-67/h15-17,22-23,27-30,33,35,39-42,47-51,53-56H,14,18-21,24-26,31-32,34,36-38,67H2,1-13H3,(H,71,80)(H,72,83)(H,73,85)(H,74,82)(H,75,84)(H,76,87)(H,77,89)(H3,68,70,88)/t41-,42+,47-,48-,49-,50-,51+,53-,54-,55-,56+/m0/s1

Shipping

Room temperature, or blue ice upon request.

AcLys-PABC-VC-Aur0101 is a novel drug conjugate designed for targeted cancer therapy. Here are some key applications of AcLys-PABC-VC-Aur0101:

Targeted Chemotherapy: AcLys-PABC-VC-Aur0101 is engineered to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. By targeting specific tumor markers, this approach increases the efficacy of chemotherapy while reducing common side effects. This precision in targeting enhances the overall treatment outcomes for patients.

Drug Delivery Systems: The conjugate structure of AcLys-PABC-VC-Aur0101 allows for the incorporation of various therapeutic payloads. Its design can be adapted to carry different drugs, making it a versatile platform for treating various types of cancers. This adaptability is crucial for personalized medicine, where treatments are tailored to individual patient's tumor profiles.

Combination Therapy: AcLys-PABC-VC-Aur0101 can be used in combination with other therapeutic agents to enhance anti-cancer efficacy. By synergizing with other drugs, it can overcome resistance mechanisms and improve treatment responses. This multi-faceted approach is essential for tackling aggressive and treatment-resistant cancers.

Tumor Imaging: The molecular structure of AcLys-PABC-VC-Aur0101 can be modified to include imaging agents, enabling its use in diagnostic imaging. This allows clinicians to visualize tumor localization and drug distribution in real-time. Such imaging capabilities are beneficial for monitoring treatment progression and optimizing therapeutic strategies.

1.Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.

Costa MJ, et al.

Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif chemokine receptor 4 (CXCR4) is attractive for targeted therapy of haematological cancers, given its expression in multiple tumour types and role in cancer "homing" to bone marrow. However, CXCR4 is also expressed in haematopoietic cells and other normal tissues, raising safety challenges to the development of anti-CXCR4 ADCs for cancer treatment. Here, we designed the first anti-CXCR4 ADC with favourable therapeutic index, effective in xenografts of haematopoietic cancers resistant to standard of care and anti-CXCR4 antibodies. We screened multiple ADC configurations, by varying type of linker-payload, drug-to-antibody ratio (DAR), affinity and Fc format. The optimal ADC bears a non-cleavable linker, auristatin as payload at DAR = 4 and a low affinity antibody with effector-reduced Fc. Contrary to other drugs targeting CXCR4, anti-CXCR4 ADCs effectively eliminated cancer cells as monotherapy, while minimizing leucocytosis. The optimal ADC selectively eliminated CXCR4+ cancer cells in solid tumours, but showed limited toxicity to normal CXCR4+ tissues, sparing haematopoietic stem cells and progenitors. Our work provides proof-of-concept that through empirical ADC design, it is possible to target proteins with broad normal tissue expression.

Catalog	Product Name	CAS	Inquiry
BADC-01741	AcLys-PABC-VC-Aur0101 intermediate-1	1609108-48-6

What is AcLys-PABC-VC-Aur0101?

AcLys-PABC-VC-Aur0101 is a cleavable linker-cytotoxin conjugate designed for ADC applications. It combines the Aur0101 cytotoxic payload with a valine-citrulline-PABC linker, facilitating selective intracellular release after ADC internalization. This ensures targeted cytotoxicity while minimizing systemic toxicity.

28/11/2020

Could you explain how AcLys-PABC-VC-Aur0101 releases its payload?

The valine-citrulline-PABC linker in AcLys-PABC-VC-Aur0101 is cleaved by lysosomal proteases after ADC internalization, releasing Aur0101 directly inside target cells. This selective mechanism enhances therapeutic efficacy and reduces off-target effects in circulation.

9/8/2021

We would like to know the research applications of AcLys-PABC-VC-Aur0101.

AcLys-PABC-VC-Aur0101 is used in oncology ADC research for hematologic and solid tumors. Its protease-cleavable linker allows evaluation of intracellular drug release, pharmacokinetics, and cytotoxicity, supporting preclinical and early-stage clinical studies.

26/12/2018

What stability characteristics does AcLys-PABC-VC-Aur0101 offer?

This conjugate exhibits high plasma stability due to the valine-citrulline-PABC linker, reducing premature payload release. The design maintains ADC integrity during circulation, ensuring predictable drug delivery and consistent experimental results.

1/9/2018

Good afternoon! Could you tell me if AcLys-PABC-VC-Aur0101 can be conjugated to different antibodies?

Yes, AcLys-PABC-VC-Aur0101 can be conjugated to various monoclonal antibodies via cysteine or lysine residues. This enables flexible ADC design, adjustment of drug-antibody ratios, and adaptation to specific target antigens for research purposes.

15/8/2021

— Dr. Victoria Reed, ADC Chemist (UK)

AcLys-PABC-VC-Aur0101 allowed us to complete complex linker conjugation with excellent yields.

26/12/2018

— Dr. Jason Miller, Senior Scientist (USA)

I appreciated the rapid delivery and full QC reports; AcLys-PABC-VC-Aur0101 performed flawlessly in our assays.

15/8/2021

— Dr. Michael Johnson, Drug Development Scientist (Canada)

AcLys-PABC-VC-Aur0101 from BOC Sciences was delivered right on time and with full supporting data. The compound’s bioactivity in our validation models confirmed their technical credibility and commitment to quality.

1/9/2018

— Ms. Chloe Dubois, Principal Scientist (France)

As a small biotech, we rely on partners who can deliver quality and support. The AcLys-PABC-VC-Aur0101 from BOC Sciences was key to our early-stage ADC program. The product's solubility and stability were excellent, streamlining our conjugation process and accelerating our research. They are a great collaborator for us.

28/11/2020

— Ms. Audrey Dupont, Research Scientist (France)

A highly pure and stable product. AcLys-PABC-VC-Aur0101 streamlined our conjugation process and accelerated our research pipeline. A great supplier.

— Dr. Emily Clark, Principal Scientist (UK)

AcLys-PABC-VC-Aur0101 arrived with robust documentation and excellent batch purity. The compound behaved as expected in cytotoxicity assays, proving BOC Sciences’ reliability in ADC materials.

9/8/2021